神威药业(02877)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02877 神威药业

休市中 09-04 16:08:03

8.260

+0.070

+0.85%

最高8.320	最低8.150	成交量147.80万
今开8.245	昨收8.190	日振幅2.08%
总市值68.31亿	流通市值68.31亿	总股本8.27亿
成交额1,216万	换手率0.18%	流通股本8.27亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02877","market":"HK","secType":"STK","nameCN":"神威药业","latestPrice":8.26,"timestamp":1788509283008,"preClose":8.19,"halted":0,"volume":1478000,"delay":0,"changeRate":0.008547008547008583,"floatShares":827000000,"shares":827000000,"eps":1.26,"marketStatus":"休市中","change":0.07,"latestTime":"09-04 16:08:03","open":8.245,"high":8.32,"low":8.15,"amount":12164393,"amplitude":0.020757,"askPrice":8.265,"askSize":3000,"bidPrice":8.26,"bidSize":11000,"shortable":3,"etf":0,"ttmEps":1.12,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1788744600000},"marketStatusCode":7,"adr":0,"listingDate":1101916800000,"exchange":"SEHK","adjPreClose":8.19,"dividendRate":0.073475,"openAndCloseTimeList":[[1788485400000,1788494400000],[1788498000000,1788508800000]],"volumeRatio":0.873935770296818,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02877","defaultTab":"news","newsList":[{"id":"1115054932","title":"神威药业8月股份变动月报：股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1115054932","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1115054932?lang=zh_cn&edition=full","pubTime":"2026-09-01 16:33","pubTimestamp":1788251597,"startTime":"0","endTime":"0","summary":"中国神威药业集团有限公司（股票代码：02877）于2026年9月1日披露截至2026年8月31日的股份变动月报。根据公告，报告期内公司法定注册股本维持在5,000,000,000股，面值每股0.1港元，总额500,000,000港元，未出现增减变动。\n同期，公司已发行股份数量为827,000,000股，并无库存股，较上月无增减变化。公告显示，报告期内公司未进行任何股份发行、股份购回或注销，也未有股权激励及期权变动事项。公司确认当前已满足适用的公众持股量要求，股本总体保持稳定。\n公告由公司秘书李品正签署，公司声明将继续遵守香港联合交易所有限公司相关上市规则及适用法律法规。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662775280","title":"神威药业午后涨逾5% 上半年营业额11.81亿元同比减少28.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662775280","media":"新浪港股","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662775280?lang=zh_cn&edition=full","pubTime":"2026-08-27 14:54","pubTimestamp":1787813640,"startTime":"0","endTime":"0","summary":"模拟交易客户端神威药业午后一度飙升12%，截至发稿，股价上涨4.92%，现报8.33港元，成交额5423.40万港元。神威药业发布中期业绩，上半年营业额11.81亿元人民币，同比减少28.5%；期内溢利4.69亿元，同比减少23.7%；每股基本盈利62分；拟派发第二次中期股息80分。于2026年首6个月，口服产品占总销售额的比例达72.9% ，而注射液产品则占总销售额27.1%。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-08-27/doc-inipttax5893795.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1191","02877","BK1606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662778977","title":"港股异动 | 神威药业(02877.HK)午后飙升12% 上半年业绩下滑超两成 拟派发第二次中期股息80分","url":"https://stock-news.laohu8.com/highlight/detail?id=2662778977","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662778977?lang=zh_cn&edition=full","pubTime":"2026-08-27 13:41","pubTimestamp":1787809288,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1606","BK1191","02877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662727991","title":"神威药业(02877)发布中期业绩 期内溢利4.69亿元 同比减少23.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662727991","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662727991?lang=zh_cn&edition=full","pubTime":"2026-08-27 12:12","pubTimestamp":1787803973,"startTime":"0","endTime":"0","summary":"智通财经APP讯，神威药业 发布2026年中期业绩，该集团期内取得营业额11.81亿元人民币，同比减少28.5%;期内溢利4.69亿元，同比减少23.7%;每股基本盈利62分;拟派发第二次中期股息80分。清开灵注射液和参麦注射液销售额比去年同期分别减少49.0%及51.3% ，而舒血宁注射液、冠心宁注射液、及丹参注射液等多个注射液产品的销售额亦分别减少39.1%、23.7%及 34.5%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1486786.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02877","BK1191","BK1606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190311861","title":"神威药业二零二六年中期营收11.81亿元 净利润4.69亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1190311861","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1190311861?lang=zh_cn&edition=full","pubTime":"2026-08-27 12:06","pubTimestamp":1787803577,"startTime":"0","endTime":"0","summary":"神威药业公布二零二六年中期财报，实现营业收入11.81亿元，同比下降28.5%。期内净利润4.69亿元，同比下降23.7%。毛利率为69.9%，较上年同期的72.2%有所下滑。成本方面，销售及分销成本下降51.8%，占营业额比重由上年同期的39.2%降至26.4%；行政开支同比减少15.5%，占营业额比重由上年同期的7.7%升至9.0%；研发投入占比5.7%，上年同期为3.0%。神威药业以注射液与口服制剂为主要业务。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"神威药业二零二六年中期营收11.81亿元 净利润4.69亿元","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109912163","title":"神威药业定于2026年8月27日召开董事会审议中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1109912163","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1109912163?lang=zh_cn&edition=full","pubTime":"2026-08-17 16:36","pubTimestamp":1786955803,"startTime":"0","endTime":"0","summary":"中国神威药业集团有限公司（02877）8月17日公告，公司董事会将于2026年8月27日（星期四）召开会议，拟审议并批准截至2026年6月30日止六个月的中期业绩，同时考虑宣派股息事宜。\n公告显示，公司现任董事会成员包括：  \n1. 执行董事：李振江、信蕴霞、李惠民  \n2. 非执行董事：周文成  \n3. 独立非执行董事：廖舜辉、姚逸安、王桂华\n以上会议结果及相关财务数据将在会后发布。公司提醒投资者留意后续公告。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171658554","title":"神威药业7月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1171658554","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1171658554?lang=zh_cn&edition=full","pubTime":"2026-08-03 15:40","pubTimestamp":1785742843,"startTime":"0","endTime":"0","summary":"2026年8月3日，中国神威药业集团有限公司公布截至2026年7月31日的每月证券变动情况。根据月报显示，公司报告期内注册股本及已发行股本均维持稳定，未发生新增发行、回购或注销股份等变化。另据公告，由于本月未进行股权激励、期权计划或其他涉及发行人股份的协议安排，上述股份总数保持不变。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651584492","title":"【券商聚焦】光大证券：议优先布局经营稳健、业绩扎实或者股息类中药标的","url":"https://stock-news.laohu8.com/highlight/detail?id=2651584492","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651584492?lang=zh_cn&edition=full","pubTime":"2026-07-16 08:54","pubTimestamp":1784163265,"startTime":"0","endTime":"0","summary":"金吾财讯 | 光大证券研究指，近期，中药板块持续上涨，主要受到市场避险、政策利好、业绩催化和估值底部等多重因素共同推动，中期配置价值显著，后市偏乐观。建议优先布局经营稳健、业绩扎实或者高股息类中药标的。","market":"us","thumbnail":"https://static.szfiu.com/news/20250109/MjJmNDVlM2IxNTc1MzAyMDFjYTFhODQyNzEzMTQ0NzU5OA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MjJmNDVlM2IxNTc1MzAyMDFjYTFhODQyNzEzMTQ0NzU5OA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1985990","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01643","02273","BK1606","BK1191","BK1570","VIG","00874","BK0276","BK4585","03320","BK1147","03613","BK1515","02877","BK0012","BK0183","02161","00570","601788","06178","BK1564","BK0028","BK1197","BK0188","BK1521","BK4588","BK1219","KCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183201976","title":"神威药业6月股份变动月报：股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1183201976","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1183201976?lang=zh_cn&edition=full","pubTime":"2026-07-03 10:38","pubTimestamp":1783046298,"startTime":"0","endTime":"0","summary":"中国神威药业集团有限公司于2026年7月3日发布截至2026年6月30日的6月股份变动月报。公告显示，公司本期注册股本及已发行股份数均与上月持平，股本保持稳定。根据公告，公司法定/注册股本在报告期初和期末均为50亿股普通股，每股面值为港币0.10元，合计注册股本为港币5亿元。报告期内，未发生与股份相关的新增发行、购回、注销或库存股份变动。整体来看，神威药业在2026年6月并未发生任何股份变动，公司股本规模保持不变。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139336923","title":"神威药业5月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1139336923","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1139336923?lang=zh_cn&edition=full","pubTime":"2026-06-01 10:41","pubTimestamp":1780281669,"startTime":"0","endTime":"0","summary":"中国神威药业集团有限公司于2026年6月1日发布截至2026年5月31日的股份变动月报表。报告显示，公司本月法定/注册股本为50亿股，每股面值为0.1港元，对应法定/注册股本总额5亿港元，与上月底相比无变动。报告期内，公司不存在新增发行、股份购回、注销或库存股份数量变动情况。截至5月末，公司确认已符合适用的公众持股量要求，各类上市规则及相关法规要求均已遵守。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633111806","title":"神威药业(02877)第一季度营业额达6.24亿元 同比减少18.0%","url":"https://stock-news.laohu8.com/highlight/detail?id=2633111806","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2633111806?lang=zh_cn&edition=full","pubTime":"2026-05-07 17:15","pubTimestamp":1778145306,"startTime":"0","endTime":"0","summary":"以产品剂型分析，2026年第一季度，注射液产品、软胶囊产品、颗粒剂产品及中药配方颗粒产品分别占集团的营业总额约26.9%、17.1%、23.4%及26.3%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1439080.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1606","02877","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125276207","title":"神威药业4月股份变动月报：股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1125276207","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1125276207?lang=zh_cn&edition=full","pubTime":"2026-04-30 16:36","pubTimestamp":1777538188,"startTime":"0","endTime":"0","summary":"中国神威药业集团有限公司于2026年4月30日发布4月股份变动月报，报告期为2026年4月。根据公告，公司本月法定/注册股本仍为5,000,000,000股，面值每股港币0.1元，总额港币500,000,000元。上述注册股本在4月无变动。截至4月30日，公司普通股已发行股本为827,000,000股，与上月底保持一致，月内无任何新增发行、购回、注销或库藏股活动。公司表示，已遵守香港联合交易所有限公司的相关上市规则及所有适用的法律和监管规定。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188756172","title":"神威药业2025年收入跌至31.35亿元，净利润逆势增长继续攀升","url":"https://stock-news.laohu8.com/highlight/detail?id=1188756172","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1188756172?lang=zh_cn&edition=full","pubTime":"2026-04-23 17:19","pubTimestamp":1776935992,"startTime":"0","endTime":"0","summary":"神威药业于2025年实现营业额31.35亿元人民币，相较2024年的37.78亿元有所下滑，但在盈利能力方面保持稳步提升。除税前溢利同比增长10.8%至12.69亿元人民币，股东应占溢利为9.50亿元人民币，较上年度的8.40亿元增长13.0%，体现出公司在外部市场环境持续承压的情况下仍具备较强的盈利韧性。报告期内，毛利为22.66亿元人民币，毛利率约72.3%，净利率约30.4%，均基本维持在公司近年较高水准。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"神威药业2025年收入跌至31.35亿元，净利润逆势增长继续攀升","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628277713","title":"港股异动 | 神威药业(02877)涨超4% 桃红四物汤颗粒获批上市 公司经典名方研发已进入集中产出期","url":"https://stock-news.laohu8.com/highlight/detail?id=2628277713","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2628277713?lang=zh_cn&edition=full","pubTime":"2026-04-20 11:18","pubTimestamp":1776655089,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，神威药业涨超4%，截至发稿，涨4.55%，报10.33港元，成交额1032.12万港元。神威药业成为河北省首家取得该品种批准文号的企业。今年以来，神威药业已连续斩获3款经典名方批文，持续丰富集团经典名方产品矩阵，加速中医药经典名方成果转化为临床生产力。目前，神威药业集团经典名方获批数量已增至7款，获批数量继续保持全国首位，领跑全国。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1430512.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","BK4588","BK1191","BK1606","IPOS","02877","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185572774","title":"神威药业3月股份变动月报：无新增发行，股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1185572774","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1185572774?lang=zh_cn&edition=full","pubTime":"2026-04-01 10:25","pubTimestamp":1775010318,"startTime":"0","endTime":"0","summary":"神威药业（02877）于2026年4月1日发布截至2026年3月31日的股份变动月报表。公告显示，本月公司法定股本和已发行股份均未发生变动。以下为具体情况：\n神威药业法定股本维持5,000,000,000股，每股面值港币0.1元，总额为港币500,000,000元；本月底已发行普通股数量维持827,000,000股，与上月底持平。本月无任何新增发行、购回、注销或库藏股变动。\n公告同时明确，无股份期权、可换股票据和股权激励计划的新增或变动事项。截至报告期末，公司股本结构保持稳定。公司并确认已遵守香港联交所《上市规则》和相关法律法规。\n本公告由公司秘书李品正签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156915571","title":"异动解读 | 神威药业发布强劲年度业绩并派发股息，盘中大涨5.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=1156915571","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1156915571?lang=zh_cn&edition=full","pubTime":"2026-03-27 13:20","pubTimestamp":1774588852,"startTime":"0","endTime":"0","summary":"神威药业今日盘中股价大幅上涨5.09%，引起了市场的高度关注。消息面上，公司于盘前发布了截至2025年12月31日止的年度业绩报告。报告显示，尽管面临市场挑战，公司年度净利润达到人民币9.5亿元，同比上升13.1%，展现了稳健的盈利能力。同时，公司宣布派发2026年第一次中期股息，每股人民币0.43元，体现了对股东回报的重视和公司良好的现金流状况。这些积极的财务和业务进展共同提振了投资者信心，推动了股价在交易时段的显著上扬。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184622630","title":"神威药业将于2026年05月19日派发中期股息每股0.43元","url":"https://stock-news.laohu8.com/highlight/detail?id=1184622630","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1184622630?lang=zh_cn&edition=full","pubTime":"2026-03-27 12:20","pubTimestamp":1774585245,"startTime":"0","endTime":"0","summary":"神威药业(02877)于2026年3月27日发布公告，董事会宣布派发截至2026年12月31日止年度的第一次中期股息，每股股息人民币0.43元，并按1人民币兑1.132港元计算，每股折合约0.487港元。\n公告显示，本次股息的除净日为2026年5月4日，股东须于2026年5月5日16:30前办理股份过户登记手续。股份过户登记将于2026年5月6日至5月7日暂停办理，记录日期为2026年5月7日。该股息将于2026年5月19日派发。\n根据公告，本次股息性质为普通股息，代扣所得税信息为“不适用”。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622814158","title":"神威药业(02877)发布年度业绩 净利润9.5亿元 同比上升13.1% 集采中标八大产品夯实市场基础","url":"https://stock-news.laohu8.com/highlight/detail?id=2622814158","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2622814158?lang=zh_cn&edition=full","pubTime":"2026-03-27 12:18","pubTimestamp":1774585119,"startTime":"0","endTime":"0","summary":"智通财经APP讯，神威药业 发布截至2025年12月31日止财政年度全年业绩，集团营业额为人民币31.35亿元，比去年下降17.0%;毛利率为72.3%，而去年为75.0%;年度溢利为人民币9.5亿元，比去年上升13.1%;每股盈利为人民币126分;及宣派2026年第一次中期股息每股人民币43分。行业整体于年内出现销售下降，本集团中药配方颗粒销售收入亦减少了14.4%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1420268.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113206235","title":"神威药业2015年收入下降17%但净利润同比增长13.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=1113206235","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1113206235?lang=zh_cn&edition=full","pubTime":"2026-03-27 12:08","pubTimestamp":1774584517,"startTime":"0","endTime":"0","summary":"神威药业于截至2015年12月31日止年度实现营业额约人民币31.35亿元，同比下降17.0%。其中，注射液产品营业额约人民币10.16亿元，占比32.4%，同比减少19.8%；颗粒剂产品约人民币5.43亿元，同比下降19.4%；软膏药产品约人民币4.36亿元，同比下降12.0%；中药配方颗粒产品约人民币9.34亿元，同比下降14.4%，占集团整体营业额29.8%；其他制剂产品约人民币2.07亿元，占比6.6%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620541036","title":"神威药业(02877.HK)3月27日举行董事会会议批准发布年度业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2620541036","media":"中金财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2620541036?lang=zh_cn&edition=full","pubTime":"2026-03-17 12:27","pubTimestamp":1773721623,"startTime":"0","endTime":"0","summary":"格隆汇3月17日丨神威药业(02877.HK)宣布，公司将于2026年3月27日星期五于香港湾仔港湾道18号中环广场31楼3109室举行董事会会议，藉以(其中包括)批准发布公司及其附属公司截至2025年12月31日止年度业绩及考虑宣派股息。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260317/32074147.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["02877","BK1191","BK1606"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.shineway.com.hk","stockEarnings":[{"period":"1week","weight":-0.0305},{"period":"1month","weight":0.0377},{"period":"3month","weight":-0.0248},{"period":"6month","weight":-0.0475},{"period":"1year","weight":0.0457},{"period":"ytd","weight":0.0111}],"compareEarnings":[{"period":"1week","weight":0.0026},{"period":"1month","weight":-0.0102},{"period":"3month","weight":0.0276},{"period":"6month","weight":-0.0041},{"period":"1year","weight":0.0236},{"period":"ytd","weight":0.0008}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"中国神威药业集团有限公司是一家主要从事中药产品研发、制造及买卖的投资控股公司。该公司的产品剂型包括注射液、软胶囊、颗粒剂、中药（TCM）配方颗粒、口服产品及其他剂型。该公司的产品包括清开灵注射液、参麦注射液、五福心脑清软胶囊、清开灵软胶囊、滑膜炎颗粒、复方甘草片等产品，应用于流感、心脑血管、呼吸系统等疾病领域。该公司在中国大陆和香港市场运营其业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.681818,"avgChangeRate":0.030886},{"month":2,"riseRate":0.545455,"avgChangeRate":0.033621},{"month":3,"riseRate":0.590909,"avgChangeRate":0.015717},{"month":4,"riseRate":0.681818,"avgChangeRate":0.049924},{"month":5,"riseRate":0.5,"avgChangeRate":0.030774},{"month":6,"riseRate":0.363636,"avgChangeRate":-0.025627},{"month":7,"riseRate":0.227273,"avgChangeRate":-0.052689},{"month":8,"riseRate":0.454545,"avgChangeRate":-0.000542},{"month":9,"riseRate":0.318182,"avgChangeRate":-0.000907},{"month":10,"riseRate":0.666667,"avgChangeRate":0.016603},{"month":11,"riseRate":0.52381,"avgChangeRate":0.056969},{"month":12,"riseRate":0.47619,"avgChangeRate":-0.002697}],"exchange":"SEHK","name":"神威药业","nameEN":"SHINEWAY PHARM"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"神威药业(02877)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供神威药业(02877)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"神威药业,02877,神威药业股票,神威药业股票老虎,神威药业股票老虎国际,神威药业行情,神威药业股票行情,神威药业股价,神威药业股市,神威药业股票价格,神威药业股票交易,神威药业股票购买,神威药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"神威药业(02877)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供神威药业(02877)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}